ADMA Biologics Announces Fourth Quarter and Full Year 2023 F

28.02.2024 - 4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income(2) of $8.5 Million; FY 2023 Adjusted Net ...

Related Keywords

United States , Boca Raton , Florida , Adam Grossman , Michelle Pappanastos , Biologics Inc , Nasdaq , Business Development , Exchange Commission , Drug Administration , Revenue Guidance Increased , More Than , Income Guidance Increased , Growth Opportunities Targeting Manufacturing , New Pipeline Hyperimmune Globulin , Advance During , Call Scheduled , Chief Executive Officer , Growth Opportunities , Production Yield Enhancement , Pipeline Introduction , Hyperimmune Globulin , United States Food , Private Securities Litigation Reform Act , Corporate Strategy , Managing Director , Argot Partners , Months Ended December , Ended December ,